Charlotte Cassell
Family · Mount Airy, NCNPI 1831269091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 92 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $959 and has fallen 95.1% since, to $47 in 2025.
Across 92 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$162
- Amgen$136
- Takeda Pharmaceuticals U.S.A., Inc.$124
- Amarin Pharma, Inc.$88
- Biohaven Pharmaceutical Holding Company Ltd.$87
- Astellas Pharma US Inc$81
- plus $781 from 22 others
What the payments were for
- Food & beverage$1,44799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $162 |
| Amgen | 8 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $124 |
| Amarin Pharma, Inc. | 5 | $88 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $87 |
| Astellas Pharma US Inc | 5 | $81 |
| GSK | 5 | $80 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $76 |
| AbbVie | 5 | $71 |
| Merck | 3 | $62 |
| Pfizer | 4 | $56 |
| Biohaven Pharmaceuticals, Inc. | 4 | $54 |
| Boehringer Ingelheim | 3 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Bayer | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Mylan Specialty L.p. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Abbott | 1 | $25 |
| Organon | 2 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Eisai Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Smith+Nephew | 1 | $15 |
| Novartis | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,460 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Topiramate | 16 | $84 |
Paid to pharmacies, not to this prescriber.
Other family in Mount Airy
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.